Advertising regulator clears ‘dead rat’ cinema ad
May 11, 2009Sales and Marketing counterfeits
Pfizer's hard-hitting advert about the dangers of using counterfeit medicines did not breach advertising regulations, according to the Advertising Standards …
Allergan closes doors on Irish plant
May 8, 2009Manufacturing and Production Allergan
US drugmaker Allergan has brought the curtain down on its manufacturing facility in Arklow, Ireland, months ahead of schedule. The …
Pharma must go further with its collaborations
May 8, 2009Research and Development, Sales and Marketing pwC, strategy
Pharma companies will soon have to start collaborating with companies outside the healthcare sector.The global economic situation will make this …
Servier signs drug discovery deal with Vernalis
May 7, 2009Research and Development, Sales and Marketing Servier, Vernalis
Servier, France's largest privately-owned pharma company, has signed a new three-year drug discovery deal with Vernalis focused on oncology. UK …
NICE rejects Nexavar for liver cancer
May 7, 2009Research and Development, Sales and Marketing Bayer, NICE, Nexavar
NICE has rejected Nexavar as a treatment for liver cancer, saying it is not a cost-effective use of NHS resources. …
Avastin approved for aggressive brain tumour
May 7, 2009Sales and Marketing GBM, avastin
Roche has gained US approval for Avastin in people with the aggressive brain cancer glioblastoma multiforme (GBM). The drug can …
Novo Nordisk plans summer launches for new diabetes drug
May 7, 2009Research and Development, Sales and Marketing Novo Nordisk, Victoza, diabetes
Novo Nordisk is preparing Victoza for a summer launch into its first European markets, including the UK, after it was …
NHS should be ‘jewel in the crown’ for UK biotech
May 7, 2009Research and Development NICE
The NHS could be the 'jewel in the crown' of UK medical research, if it would only assist in clinical …
Sanofi-Aventis makes 200m euro push into antibodies
May 7, 2009Manufacturing and Production Sanofi-Aventis, biologicals
Sanofi-Aventis will spend 200 million euros to convert one of its facilities near Paris into a biotechnology facility which is …
Building better relations with tomorrow’s doctors
May 6, 2009Sales and Marketing doctors, industry relations
A huge amount of time and money is spent by the pharma industry on interacting with the medical community and …
Bayer launches UK television ads for its morning-after pill
May 6, 2009Sales and Marketing Bayer
Bayer Schering Pharma has launched a television advertising campaign for its morning-after pill Levonelle One Step in the UK. The …
Pharma manufacturing: news in brief
May 6, 2009Manufacturing and Production Pfizer
Pharmafocus presents a round-up of developments in the pharmaceutical manufacturing sector, including Pfizer's increased adoption of contract manufacturing and facility …
Ranbaxy woes continue with antibiotic recall
May 6, 2009Sales and Marketing Ranbaxy, US
Indian drugmaker Ranbaxy Laboratories has recalled an antibiotic on sale in the US, suggesting that it still has some way …
Bayer Schering’s contraceptive patch enters phase III
May 5, 2009Research and Development, Sales and Marketing Bayer, sexual health
Bayer Schering is to start phase III trials of its new contraceptive patch and anticipates submitting the product for regulatory …
EDQM takes issue with more Chinese APIs
May 5, 2009Manufacturing and Production Asia, China
The European Directorate on the Quality of Medicines has suspended the certificates of suitability (CEPs) of four active pharmaceutical ingredients …
Coast first casualty in US overhaul of IRB system
May 5, 2009Research and Development FDA, US
A US company offering institutional review board services to sponsors of clinical trials has been forced to close its doors …
Pfizer dips in first quarter
May 1, 2009Sales and Marketing Pfizer
Pfizer saw its performance dip in the first quarter of 2009, with revenue down 8% year-on-year. The company, which is …
Biotech partnering in the credit crunch
May 1, 2009Research and Development biotech, partnering, pharma
Action Pharma’s Torben Jung Laursen explores the new challenges facing pharma-biotech partnering as a result of the economic downturn.In today’s …
BMS turns in solid first quarter results
May 1, 2009Sales and Marketing BMS
Bristol-Myers Squibb turned in respectable figures for the first quarter of 2008, with net income up 5% to $921 million. …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
